A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAF mutant advanced melanoma (INTERIM).
Dayimu, Alimu Gupta, Avinash Matin, Rubeta N Nobes, Jenny Board, Ruth Payne, Miranda Rao, Ankit Fusi, Alberto Danson, Sarah Eccles, Bryony
Dayimu, Alimu
Gupta, Avinash
Matin, Rubeta N
Nobes, Jenny
Board, Ruth
Payne, Miranda
Rao, Ankit
Fusi, Alberto
Danson, Sarah
Eccles, Bryony
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2023-11-24
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
BRAF+MEK inhibitors extend life expectancy of patients with BRAFV600 mutant advanced melanoma. Acquired resistance limits duration of benefit, but preclinical and case studies suggest intermittent dosing could overcome this limitation. INTERIM was a phase 2 trial evaluating an intermittent dosing regimen.
Citation
McLornan DP, Psaila B, Ewing J, Innes A, Arami S, Brady J, Butt NM, Cargo C, Cross NCP, Francis S, Frewin R, Garg M, Godfrey AL, Green A, Khan A, Knapper S, Lambert J, McGregor A, McMullin MF, Nangalia J, Neelakantan P, Woodley C, Mead A, Somervaille TCP, Harrison CN; BSH Committee. The management of myelofibrosis: A British Society for Haematology Guideline. Br J Haematol. 2024 Jan;204(1):136-150. doi: 10.1111/bjh.19186. Epub 2023 Dec 1
Type
Article